Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2026 First Extraordinary General Meeting

Time:2026-09-04

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Proposed 2026 Interim Profit Distribution Plan of the Company

Time:2026-09-04

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Drug Registration Certificate

Time:2026-08-27

Ad hoc announcement pursuant to Art. 53 JCARE 2026 Interim Report

Time:2026-08-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Drug Registration Certificate

Time:2026-07-23

Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2025 Profit Distribution of JCARE

Time:2026-06-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Acceptance of Application for Marketing Authorization for Lecankitug Injection

Time:2026-06-01

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Drug Registration Certificate

Time:2026-06-01

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2025 Annual General Meeting

Time:2026-06-01

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Progress of the Public Tender Offer by the Controlled Subsidiary Livzon Group for Equity of Vietnam IMP and Completion of Ownership Transfer

Time:2026-05-11

< 1234...16 >